Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Metastatic melanoma prognosis has improved due to novel therapies.
• BRAF V600 mutations activate the MAPK pathway in 45% of melanoma patients.
• BRAF and MEK inhibitors offer rapid responses but face secondary resistance.

Purpose of the Study:

• To review current and emerging treatments for metastatic melanoma.
• To discuss toxicities and decision-making algorithms for melanoma therapy.
• To explore strategies for overcoming resistance to anti-PD-1 therapy.

Main Methods:

• Review of existing literature on melanoma therapeutics.
• Analysis of clinical trial data for BRAF/MEK inhibitors and immune checkpoint inhibitors.
• Discussion of treatment sequencing and combination strategies.

Main Results:

• Anti-PD-1 antibodies prolong survival and offer potential cures in some melanoma patients.
• BRAF and MEK inhibitors provide initial responses but are limited by resistance.
• Combination therapies and targeting tumor microenvironment are key to overcoming resistance.

Conclusions:

• Further research is needed as 50% of patients lack long-term benefits.
• Optimizing anti-PD-1 therapy by combining with other treatments is crucial.
• Melanoma treatment advancements are paving the way for other cancer therapies.